Budesonide Inhalation Suspension
Product Images NDC 68788-8503

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Budesonide Inhalation (NDC 68788-8503). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (3315e8ee F729 4dab 86e4 349ab1c9c9ca 01)

Chemical structure diagram of budesonide, the active ingredient in budesonide inhalation suspension. The structure shows the detailed arrangement of atoms and bonds characteristic of the corticosteroid budesonide.*

FDA Label Image

Image (3315e8ee F729 4dab 86e4 349ab1c9c9ca 02)

A line graph showing the mean change from baseline in nighttime asthma symptoms over 12 weeks for budesonide inhalation suspension at doses of 0.25 mg, 0.5 mg, and 1.0 mg once daily compared to placebo. The graph displays symptom changes at multiple time points from baseline to week 10-12, with all budesonide doses showing greater symptom improvement than placebo. Associated p-values indicate statistical significance for each dose.*

FDA Label Image

Image (3315e8ee F729 4dab 86e4 349ab1c9c9ca 03)

A line graph showing nighttime asthma change from baseline over weeks 0 to 12. The y-axis represents mean change from baseline in nighttime asthma symptoms, and the x-axis shows time points from baseline to weeks 10-12. Three lines represent placebo, 0.25 mg twice daily, and 0.5 mg twice daily groups, with both medication doses showing greater symptom improvement than placebo. P-values for 0.25 mg and 0.5 mg are 0.022 and 0.021, respectively.*

FDA Label Image

Image (3315e8ee F729 4dab 86e4 349ab1c9c9ca 04)

A line graph titled 'Nighttime Asthma Change from Baseline' showing mean change in nighttime asthma symptoms over weeks 0 to 12. Five groups are compared: placebo, 0.25 mg once daily, 0.25 mg twice daily, 0.5 mg twice daily, and 1.0 mg once daily. The y-axis indicates mean change from baseline symptoms, with values decreasing over time for treatment groups compared to placebo.*

FDA Label Image

Image (3315e8ee F729 4dab 86e4 349ab1c9c9ca 05)

FDA Label Image

Image (3315e8ee F729 4dab 86e4 349ab1c9c9ca 06)

An instructional illustration showing a person holding a blister pack of medication and pushing a tablet or capsule out by pressing on the back of the pack with their thumb. The image demonstrates the proper method for extracting a dose from a blister pack.*

FDA Label Image

Image (3315e8ee F729 4dab 86e4 349ab1c9c9ca 07)

An instructional illustration showing a hand holding a single-dose vial of budesonide inhalation suspension, with a curved arrow indicating the vial should be rotated or shaken before use.*

FDA Label Image

Image (3315e8ee F729 4dab 86e4 349ab1c9c9ca 08)

An instructional line drawing showing a person holding a budesonide inhalation suspension vial with both hands, twisting off the top cap to open it. The arrow indicates the direction to turn for opening the vial.*

FDA Label Image

Image (3315e8ee F729 4dab 86e4 349ab1c9c9ca 09)

An instructional black-and-white line drawing showing a person holding an inhaler and introducing a liquid from a small vial or ampule into the inhaler device, illustrating the preparation or loading step for budesonide inhalation suspension.*

FDA Label Image

Image (3315e8ee F729 4dab 86e4 349ab1c9c9ca 10)

FDA Label Image

Budesonide Inh Susp 0.5mg/2ml (3315e8ee F729 4dab 86e4 349ab1c9c9ca 11)

Label for Budesonide Inhalation Suspension 0.5 mg/2 mL, a respiratory inhalation suspension by Preferred Pharmaceuticals, Inc. The label notes generic for Pulmicort and provides usage/storage instructions. It includes storage temperatures, handling cautions, manufacturer Lupin Pharmaceuticals, Inc., barcode, and a caution about federal law prohibiting drug transfer. Spanish instructions section is also highlighted.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.